February 28, 2026/
This article provides a comprehensive medical overview of rare diseases, with a dual focus: first, on drug-induced rare diseases as adverse reactions, and second, on the critical risk-benefit calculus for...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
This article provides a comprehensive medical overview of rare diseases, with a dual focus: first, on drug-induced rare diseases as adverse reactions, and second, on the critical risk-benefit calculus for...
From a pharmacovigilance standpoint, Ramadan represents a period of systematic medication schedule disruption, altered drug pharmacokinetics, and increased vulnerability to adverse drug reactions (ADRs).
Significant label update regarding mesalazine and idiopathic intracranial hypertension, a detailed local case report on warfarin-food interaction leading to ischemic stroke
